Walter Bordogna

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Tony Mok, D. Ross Camidge, Shirish M. Gadgeel et al. · Annals of Oncology · 2020 · 686 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris et al. · Journal of Clinical Oncology · 2015 · 583 citations

Medicine, Oncology, Pharmacology +13

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

D. Ross Camidge, Rafał Dziadziuszko, Solange Peters et al. · Journal of Thoracic Oncology · 2019 · 491 citations · Full text

Medicine, Oncology, Pharmacology +15

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Alice T. Shaw, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2016 · 196 citations · Full text

Medicine, Oncology, Pharmacology +14